NCT07047443View on ClinicalTrials.gov

SHR-1811 Combined With Carboplatin in the Treatment of Advanced Breast Cancer With HER2 Expression

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

18

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2029

Conditions

Breast Cancer

Interventions

DRUG

SHR- A1811

HER2 ADC

Trial Locations (1)

Unknown

Anhui Cancer Hospital, Hefei

All Listed Sponsors

lead

Anhui Provincial Cancer Hospital

OTHER